Physician profile
Stephen Brown
NPI 1568664282
$5,921.08
in general payments reported to CMS, 2019-2025
45 companies · $894 in 2025
The $894 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $600 · 2021: $1,121 · 2022: $960 · 2023: $855 · 2024: $758 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,308 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,308.11 |
| Education | $198.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $656.12 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Actelion Pharmaceuticals US, INC. | $649.49 | 2019-2025 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $478.36 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.47 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $351.24 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $279.65 | 2020-2024 | Glassia |
| Genzyme Corporation | $228.73 | 2019-2025 | |
| United Therapeutics Corporation | $216.48 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Janssen Pharmaceuticals, INC | $200.79 | 2019-2022 | |
| Shionogi INC | $193.13 | 2021-2023 | Fetroja |
| Grifols USA, LLC | $183.17 | 2020-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $171.16 | 2019-2025 | Dupixent |
| Inari Medical, INC. | $158.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $143.07 | 2022-2023 | |
| Mylan Specialty L.P. | $130.19 | 2020-2023 | Yupelri |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $129.60 | 2021-2025 | Tezspire |
| Insmed, INC. | $112.19 | 2019-2021 | |
| Baxter Healthcare | $109.70 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $102.12 | 2021-2024 | Smartvest |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Verona Pharma, INC. | $87.08 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $86.00 | 2019-2022 | |
| Philips North America LLC | $71.84 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $71.33 | 2021-2025 | Winrevair |
| Mallinckrodt Hospital Products INC. | $68.00 | 2022-2024 | Acthar |
| Gilead Sciences, INC. | $56.49 | 2019-2022 | |
| Advanced Respiratory, INC | $55.58 | 2019-2021 | |
| Inogen, INC. | $53.95 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Ambu INC. | $39.79 | 2024-2025 | |
| Nuwellis, INC. | $37.82 | 2020-2022 | |
| Vapotherm INC | $37.50 | 2022 | |
| Pfizer INC. | $31.28 | 2019-2024 | |
| Nabriva Therapeutics, Plc | $28.23 | 2020 | |
| Inspire Medical Systems, INC. | $27.11 | 2023 | Inspire |
| Abiomed | $25.33 | 2025 | |
| Sandoz INC. | $22.14 | 2020 | |
| Abbvie INC. | $21.32 | 2021 | |
| Csl Behring | $21.15 | 2020 | |
| Allergan, INC. | $20.09 | 2020 | |
| Alexion Pharmaceuticals, INC. | $17.31 | 2021 | |
| Genentech USA, INC. | $16.84 | 2019 | |
| Tactile Systems Technology INC | $14.64 | 2025 | Flexitouch Plus, Nimbl |
| Mallinckrodt Enterprises LLC | $14.05 | 2019 | |
| Shield Therapeutics INC | $13.15 | 2023 | Accrufer |
| Ceribell, INC. | $6.90 | 2023 | Ceribell Rapid Response Eeg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.